RT Journal Article
SR Electronic
T1 WITHDRAWN: Effects of antidiabetic drugs on mortality risks in individuals with type 2 diabetes: A prospective cohort study of UK Biobank participants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.19.23290214
DO 10.1101/2023.05.19.23290214
A1 Araldi, Elisa
A1 Jutzeler, Catherine R.
A1 Ristow, Michael
YR 2024
UL http://medrxiv.org/content/early/2024/08/30/2023.05.19.23290214.abstract
AB The authors have withdrawn this manuscript owing to having been informed by the UK Biobank Research Development Team that the use of a subset of prescription data in our analyses does not comply with the Control of Patient Information (COPI, 2020) notice.Specifically, ‘these prescription data could only be used for the purpose of COVID-19 research’. While we have analyzed the impact of these prescription drugs on COVID-19 mortality, as contained in the present manuscript, any additional analyses, as also contained within, appear to be incongruent with the COPI notice.We hence abide by the request of UK Biobank Research Development Team to withdraw the entire publication. We apologize for any inconvenience this may cause. It should be noted that the scientific content, methods and validity of the results in the entire publication remain unaffected by both the request and the subsequent retraction.Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.Competing Interest StatementThe authors have declared no competing interest.Funding StatementUK Biobank was established by the Wellcome Trust, Medical Research Council, Department of Health, Scottish government, and Northwest Regional Development Agency. It has also had funding from the Welsh assembly government and the British Heart Foundation. The analyses in this study were funded by the Swiss National Science Foundation (31003A_176127 and 310030_204511 to M.R., PZ00P3_186101 to C.R.J.), the ETH Career Seed Grant (1-007724 SEED-11 to E.A.), and the Holcim Stiftung (to E.A.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current study is using data from the UK Biobank. UK Biobank has obtained ethics approval from the North West Multi-Centre Research Ethics Committee (approval number: 11/NW/0382) and has obtained informed consent from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes